INVO Fertility (IVF) EBIT (2011 - 2026)

INVO Fertility (IVF) has 16 years of EBIT data on file, last reported at -$1.6 million in Q1 2026.

• On a quarterly basis, EBIT fell 32.63% year-over-year to -$1.6 million in Q1 2026; TTM through Mar 2026 was -$7.4 million, a 5.13% increase from a year earlier, with the FY2024 full-year figure at -$8.1 million, down 20.07% from the prior year.
• EBIT for Q1 2026 stood at -$1.6 million, up from -$1.6 million in the prior quarter.
• Over the last five years, EBIT for IVF reached as high as -$886290.0 in Q3 2023 and fell as low as -$3.5 million in Q4 2024.
• Historically, EBIT has averaged -$2.1 million across 5 years, with a median of -$2.0 million in 2023.
• Across the five-year window, EBIT plunged 639.82% in 2022 and jumped 64.91% in 2023, its largest moves.
• Year by year, EBIT stood at -$2.7 million in 2022, then soared by 44.51% to -$1.5 million in 2023, then tumbled by 129.65% to -$3.5 million in 2024, then soared by 52.79% to -$1.6 million in 2025, then increased by 2.72% to -$1.6 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$1.6 million in Q1 2026, -$1.6 million in Q3 2025, and -$3.0 million in Q2 2025.